Management of T1N1M0 Invasive Ductal Carcinoma

Surgical Management

Breast‑conserving surgery (lumpectomy) is preferred when the tumor can be removed with negative margins (≥1 mm for invasive disease) and an acceptable cosmetic result can be achieved. – National Comprehensive Cancer Network (NCCN) 1, 2
Mastectomy (with or without reconstruction) is indicated when breast‑conserving surgery is not feasible because of an unfavorable tumor‑to‑breast size ratio, patient preference, or inability to obtain clear margins. – NCCN 1, 3

Sentinel lymph‑node biopsy (SLNB) alone is sufficient for patients who meet ACOSOG Z0011 criteria: clinical T1‑T2, clinically node‑negative axilla, ≤2 positive sentinel nodes, no gross extracapsular extension, planned breast‑conserving surgery with whole‑breast radiation, and planned adjuvant systemic therapy. – American College of Surgeons Oncology Group (ACOSOG) Z0011 4, 2
Completion axillary lymph‑node dissection (ALND) remains standard for patients who do not meet Z0011 criteria (e.g., mastectomy without planned radiation, >2 positive sentinel nodes, or gross extracapsular extension). – ACOSOG Z0011 4, 2
The Z0011 trial demonstrated that omitting completion ALND is oncologically safe, with the proportion of patients undergoing ALND falling from 84 % to 24 % after the trial’s publication. – JAMA Surgery 5, 4
Routine completion ALND in all N1 patients constitutes overtreatment, adding morbidity (lymphedema, nerve injury) without a survival advantage. – JAMA Surgery 5, 4, 2

Whole‑breast irradiation combined with regional nodal irradiation (supraclavicular and infraclavicular nodes) is mandatory for node‑positive disease. – NCCN 1, 2, 3
Internal‑mammary node irradiation should be considered for medial/central tumors or when multiple nodes are positive. – NCCN 1, 3
Tangential breast fields that include part of the axilla are standard in patients who satisfy Z0011 eligibility. – ACOSOG Z0011 4, 2

Post‑mastectomy radiation to the chest wall and regional lymph nodes is strongly recommended for patients with 1–3 positive nodes. – NCCN 1, 3
Radiation fields should encompass the chest wall, supraclavicular and infraclavicular regions; internal‑mammary nodes may be included when appropriate. – NCCN 1, 3
Category 1 recommendation for ≥4 positive nodes; strong consideration (controversial) for 1–3 nodes. – NCCN 3

Adjuvant endocrine therapy is mandatory and should be administered sequentially after chemotherapy when chemotherapy is given. – NCCN 1, 6
For node‑positive disease, combined adjuvant chemotherapy plus endocrine therapy is recommended; the absolute benefit of chemotherapy should be individualized based on tumor biology and genomic assay results. – NCCN 1, 6
Chemotherapy and endocrine therapy provide additive benefit, but the incremental gain from chemotherapy is smaller in tumors with favorable prognosis. – NCCN 6

Adjuvant chemotherapy plus trastuzumab (Category 1) is required for all node‑positive HER2‑positive cancers regardless of tumor size. – NCCN 1, 6
A full 1‑year course of trastuzumab is recommended. – NCCN 1, 6
For T1a‑b HER2‑positive tumors (≤1 cm), the decision to use trastuzumab must balance cardiac‑toxicity risk against uncertain absolute benefit, as this subgroup was not studied in randomized trials. – NCCN 6

Adjuvant chemotherapy is indicated for all node‑positive triple‑negative disease. – NCCN 1, 6
No endocrine or targeted therapy is applicable in this subgroup. – NCCN 6

Chemotherapy should be delivered first, followed by endocrine therapy when indicated. – NCCN 6
Trastuzumab may be given concurrently with radiation therapy without compromising safety. – NCCN 3
Endocrine therapy can be administered concurrently with or sequentially after radiation based on patient‑specific considerations. – NCCN 6

Patients older than 70 years have limited trial data; treatment decisions should incorporate comorbidities and life expectancy. – NCCN 6
Radiation therapy decisions must not be based solely on favorable tumor biology; node‑positive disease mandates regional nodal irradiation irrespective of hormone‑receptor status or tumor grade. – NCCN 1, 2, 3